A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study (Q44315213)

1 December 2017

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study (English)

1 reference

1 December 2017

1 reference

1 reference

1 reference

Peter G Rose

1

1 reference

1 December 2017

John A Blessing

2

1 reference

1 December 2017

Harrison G Ball

3

1 reference

1 December 2017

James Hoffman

4

1 reference

1 December 2017

David Warshal

5

1 reference

1 December 2017

Koen DeGeest

6

1 reference

1 December 2017

David H Moore

7

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

1 December 2017

1 reference

1 December 2017

88

1 reference

1 December 2017

2

1 reference

1 December 2017

130-135

1 reference

Promotion of microtubule assembly in vitro by taxol

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Relationships between the structure of taxol analogs and their antimitotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Docetaxel administered on a weekly basis for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Docetaxel and interstitial pulmonary injury

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Nail Changes Secondary to Docetaxel (Taxotere)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900091-4

7 January 2021

10.1016/S0090-8258(02)00091-4

Identifiers

DOI

1 reference

1 December 2017

1 reference